Gut Hormone LEAP2 in Metabolism and Eating Behaviour
Thank you for your interest in our research study. This is a questionnaire to determine if you may be eligible to take part in the study.
About the study
Obesity is a major health burden, with significant economic and societal impacts. After people lose weight, it is common for them to regain it over time. This is driven in part by hormones from the gut and fat cells in the body which act on the brain to influence appetite and eating behaviour. One such hormone is ghrelin, that stimulates appetite, food intake and acts on the hunger and reward circuits in the brain. It increases in the blood when people fast or lose weight, and falls when they eat food or gain weight.
A new hormone called LEAP2 was recently discovered, which is produced by the gut, and in animal studies blocks the action of ghrelin. Blood levels of LEAP2 move in the opposite direction to ghrelin and may therefore be a potential treatment to help people lose weight initially or particularly to maintain their weight loss.
Our LEAP2 study, funded by the UK Medical Research Council, entitled, “Gut hormone LEAP2 in metabolism and eating behaviour”, will take the Hammersmith Hospital, at Imperial College London. The LEAP2 study has been ethically approved by the West London & GTAC Research Ethics Committee (REC no. 23/LO/0510).
We are recruiting healthy, mainly non-obese, volunteers for our study to investigate the role of the LEAP2 hormone in appetite, metabolism and eating behaviour. This will tell us if LEAP2 hormone has the potential to treat obesity and/or prevent weight regain
You will receive payment for your time if you take part in the LEAP2 study.
To be eligible to take part in the LEAP2 study, you need to be:
- Either male or female
- 18-60 years of age
- Without obesity (BMI 20 to 30 kg/m2)
- Stable weight (no change to weight of more than 5% over the last 3 months)
- You must NOT have had:
- a stroke
- a heart attack
- diabetes
- previous obesity surgery
- You must NOT be vegetarian, vegan, or gluten- or lactose-intolerant
- Be able to read, speak and understand spoken and written English
- Be willing to complete multiple visits to the Hammersmith Hospital (White City, London W12 0NN) over approximately 4-10 weeks (Monday to Friday only)
In order to see if you may be eligible to take part in the study we wish to ask a few questions on the following pages.
Thank you for taking the time to complete them.
Please note that this information is entirely confidential and will not be linked to anything that can identify you.
New questions will appear automatically. If they ever seem to stop please click on the NEXT button at the bottom of the page.
If you do not go to the end of the questions you and we will not know if you may be eligible.
Please click on the NEXT button below the pictures at the bottom of the page NOW to start.....
LEAP2 Study Team
Dr. Tony Goldstone, Consultant Endocrinologist and Principal Investigator
Dr. Raghav Bhargava, Clinical Research Fellow and Study Doctor
Dr. Marcela Rodriguez Flores, Study Coordinator and Study Doctor
Ms. Sandra Luur, Study Coordinator and Research TechnicianDepartment of Brain Sciences, Imperial College London, Hammersmith Hospital
Our research is supported by: